# Phase I, Open Label, Single-Dose, Four Way Crossover Study to Compare the PK of NP101 With Oral Imitrex® (50mg) in Migraine Subjects During an Acute Migraine Attack and During a Non-Migraine Period

> **NCT00723983** · PHASE1 · COMPLETED · sponsor: **NuPathe Inc.** · enrollment: 23 (actual)

## Conditions studied

- Migraine Disorders

## Interventions

- **DRUG:** Sumatriptan succinate
- **DRUG:** NP101 Study Patch

## Key facts

- **NCT ID:** NCT00723983
- **Lead sponsor:** NuPathe Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** 2009-09
- **Final completion:** 2009-09
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2016-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00723983

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00723983, "Phase I, Open Label, Single-Dose, Four Way Crossover Study to Compare the PK of NP101 With Oral Imitrex® (50mg) in Migraine Subjects During an Acute Migraine Attack and During a Non-Migraine Period". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00723983. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*